Drug intelligence / Profile preview

morphine 6-glucuronide

Development stage
Phase 3
Lead developer
CeNeS Pharmaceuticals
Modality
Small Molecules
01

Overview

Morphine 6-glucuronide (M6G) is a major active metabolite of the opioid analgesic morphine, formed in the liver by the enzyme UGT2B7. It acts as a potent agonist at the mu-type opioid receptor, with an affinity equal to or greater than that of morphine itself. M6G is responsible for much of the analgesic effect observed after administration of morphine and can provide pain relief comparable to or exceeding that of its parent compound. Unlike some other metabolites, M6G retains strong analgesic activity and may be associated with fewer side effects such as respiratory depression and postoperative nausea and vomiting. However, it can accumulate to toxic levels in patients with renal impairment due to its primary excretion via the kidneys[1][3][5][9].

Other names
morphine 6-glucuronidemorphine6-glucuronidemorphine-6-glucuronidemorphine glucuronidemorphine 6-beta-D-glucopyranosiduronidemorphine6-beta-D-glucopyranosiduronidemorphine-6-beta-D-glucopyranosiduronidemorphine 6-beta-glucuronidemorphine6-beta-glucuronidemorphine-6-beta-glucuronide
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on morphine 6-glucuronide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine 6-glucuronide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call